Good morning Barcelona!
Looking forward to day second of #WCGIC2022
Starting off with challenging #HCC cases with @DucreuxMichel @GABOUALFA Bruno Sangro Rene Adams and Thierry de Baere
New #immunotherapy kids on the block for advanced #CRC?
Very promising data presented #WCGCI2022
Botensilimab and Balstilimab —> Fc enhanced CTLA4/PD1 combination
Compelling ORR of 24%
Is there a role of liver mets for IO efficacy?
@myESMO@OncoAlert
👏Comprehensive review on BRAF V600E
doi: 10.1158/1535-7163.MCT-21-0950
👉detected in > 40 cancer types
👉BRAF inhibition effective > 20 cancer types
👉RWD in 69 cancer types
👉BRAFi/MEKi > BRAFi , but CRC + EGFRi
👉9 FDA approvals, now tumor-agnostic
@OncoAlert@myESMO
👏Understanding evolution of resistance to targeted therapy
https://t.co/cXXNuXPJal.
❓selection or de novo acquisition?
👉CaTCH: method to analyze founder clones their postselection counterparts
Proof of concept for RAFi/MEKi resistance
#precisionmedicine
#WCGIC2022#Youngoncologist sessions: 'ESMO Session: Focus on Young Oncologists, with #ESMOYOC', plus finding local & intl. mentors to build your career, #Gendermedicine in #GItumours, disparities in access to new drugs 👇
🔗 https://t.co/AEXAuRLuco
@ESMOWorldGI #GIcancer
💊💊Critical appraisal of FDA approvals: food for thoughts!
https://t.co/drFkFA0NKF
👉 71 2002-14
👉161 2017-21
👉71 IO 💉
👉 62 small molecules💊
👉 5 T-agnostic
✅ 47 with OS
❗️ 58 with ORR
❗️ 39 with PFS
❗️only 42 with subs. benefit acc.ESMO-MCBS
@myESMO#Immunotherapy
Watch on demand: today's tumor heterogeneity symposium #ILC2022 with @Valeriechew29 from 🇸🇬:
⬆️immune intratumoral heterogeneity is associated with
⬆️immunosuppressive tumor microenvironment and
⬇️clinical outcome parameters in #HCC
👉https://t.co/FxIbMecQlm
#LiverTwitter
Entertaining and informative talk by H. Wedemeyer
➡️history of discoveries of hepatitis viruses
➡️landmark publications and their
➡️impact on hepatitis treatment strategies
A grand start to the YI Symposium ⭐️(And I am NOT saying this bc he is my boss…)
This is EXACTLY what we aimed for when preparing the yi symposium: excellent speakers that take us on a journey 🧭through their field, highlighting novel developments but also dead ends. Thank you @analleo for your insights and advice!#ILC2022#LiverTwitter
Future of metabol. liver disease research: key insights from M. Vacca:
❗️Stop using 2D cultures for metabolic studies, go for precision cut liver slices
❗️multi organ on chip and
❗️advanced natural ecm organoids is what we should aim for
‼️Consensus on preclin. models are key!
��FGFR2 alterations in #cholangiocarcinoma
👉fusion: FGFR2 intron 17/exon 18 breakpoint; partner is known or novel/in-frame with FGFR2
👉rearrangement: gene is out-of-frame with ex. 17
👉truncation: loss of neg. regulatory element
👉In-Frame Deletion..
✅all druggable
@myESMO
🔥concerning data on acetaminophen for #immunotherapy@JCO_ASCO
https://t.co/3HGRQ4NjXp
👉APAP --> Treg⬆️ --> IO efficacy⬇️: ORR, PFS, OS
❗️be aware of concomitant💊💊:statins, steroids, antibiotics, proton-pump inhibitors...
@OncoAlert@myESMO
👏Excellent summary on Hyperprogression and #Immunotherapy in @trendscancer
https://t.co/dN8gY8qgWz
👉no clear definition, only retros. data
👉no biomarker
❓role of TME
✅clear need to identify patients with devastating outcome on ICI
@OncoAlert, @myESMO
YI Paula Olaizola presenting her comprehensive work on the role of NEDDylation in #cholangiocarcinoma in the abstract session
➡️targeting NEDDylation pharmacologically or genetically impacts tumor growth in vitro & in vivo
👏to new takes on CCA!
#LiverTwitter#ILC2022